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Abstract 
CCDC6 gene product is a pro-apoptotic protein 
substrate of ATM whose loss or inactivation 
enhances tumor progression. In primary tumors the 
impaired function of CCDC6 protein has been 
ascribed to CCDC6 rearrangements, to somatic 
mutations and to CCDC6 different levels in several 
neoplasia. The CCDC6 turnover is regulated in a cell 
cycle dependent manner upon post-translational 
modification events. The impairment of CCDC6 
turnover may affect cells behaviour and drug 
response. 
Keywords 
CCDC6, Apoptosis, DNA damage response, DNA 
repair, carcinogenesis, cell cycle checkpoint 
Identity 
Other names: D10S170, H4, TST1 
HGNC (Hugo): CCDC6 
Location: 10q21.2 
DNA/RNA 
Description 
The CCDC6 gene (Coiled Coil Containing 6) has 
been identified upon its frequent rearrangement with 
the RET proto-oncogene in papillary thyroid 
carcinomas (Fusco et al., 1987; Grieco et al., 1990), 
and with genes other than RET in solid and not  
solid tumours (Drechsler et al., 2007). Recently, by 
using an integrated molecular- and histopathology- 
based screening, the fusion CCDC6/RET has been 
also detected in lung adenocarcinoma, even at low 
frequency (Takeuchi et al., 2012).  
The CCDC6 gene is located on the long arm of 
chromosome 10 (10q21), and contains 9 exons that 
encode a transcript of 3 Kb showing an open reading 
frame (ORF) of 475 aa.   
The CCDC6 gene promoter, localized within 259 bp 
upstream of the ATG site, drives the gene expression 
ubiquitously in various human tissue (Tong et al., 
1995). 
In tumors harboring the RET/PTC1 rearrangement, 
the activation of RET involves chromosomal 
inversion of the long arm of chromosome 10 that 
juxtaposes the tyrosine kinase-encoding domain of 
RET, mapped at 10q11.2, to the promoter and the 
first exon of the CCDC6 gene, originally named 
H4(D10S170) (Pierotti et al., 1992). 
Pseudogene 
None reported 
Protein 
Description 
474 amino acid coiled coil protein. Its predicted 
amino-acid (aa) sequence contains a long coiled coil 
region and a putative binding domain for SH3-
proteins, suggesting its possible involvement in 
protein-protein interactions (Grieco et al., 1994).  
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Fig. 1: Putative phosphorylation sites in CCDC6 protein. The arrows indicate the ERK1/2 and the ATM kinases predicted 
phosphorylation sites. 
 
CCDC6 gene product shows extensive regions of 
alpha helices which have a high potential to adopt a 
coiled-coil conformation. Coiled-coils are formed by 
two or three alpha-helices that are strongly 
amphipathic and supercoil around each other, 
crossing at an angle of about 20- (Lupas et al., 1991). 
It has been demonstrate that such region can be 
involved in protein dimerization or oligomerization. 
CCDC6 protein is an ubiquitously expressed 65 KDa 
nuclear and cytosolic protein phosphorylated by 
ERK1/2 at serine 244 upon serum induction (Grieco 
et al., 1994; Celetti et al., 2004). In the last years, 
several large-scale phosphorylation site-mapping 
studies have recognized CCDC6 as a phosphoprotein 
(Beausoleil et al., 2004; Brill et al., 2004) (Figure 1). 
CCDC6 has been recognized as a pro-apoptotic 
protein, while the CCDC6 protein truncated at the 
carboxyterminus, such as in the fusion with different 
oncogenes, acts as dominant negative on nuclear 
localization and apoptosis induced by the wild-type 
protein (Celetti et al., 2004). CCDC6 is 
phosphorylated at T434 by the ATM kinase that 
stabilizes the protein in the nucleus in response to 
DNA damage. The loss of the CCDC6 region 
recognised by ATM kinase or the full protein 
deficiency determines an increase in cell survival, 
allows for DNA synthesis and permits cell to 
progress into mitosis, following the exposure to 
genotoxic stress (Merolla et al., 2007). 
CCDC6 gene product undergoes multiple post-
translational modifications such as sumoylation 
(Luise et al., 2012), ubiquitination (Povlsen et al., 
2012; Morra et al., 2015), and phosphorylation 
(Celetti et al., 2004; Beausoleil et al., 2004; Brill et 
al., 2004; Morra et al., 2015), suggesting that 
CCDC6 protein activity is highly regulated (Figure 
3). 
Expression 
Widely expressed, cell cycle regulated, post 
translational modified 
Function 
Proapoptotic and cell cycle regulated protein, 
involved in DNA damage and repair. 
Further supporting a role of CCDC6 in control of cell 
proliferation, it has been reported that CCDC6 
interacts with CREB1 and inhibits its cAMP-
dependent transcriptional activity (Leone et al., 
2010) in a SUMO-dependent manner (Luise et al., 
2012).  
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Fig. 2: CCDC6 interactors and modifiers. 
 
Interestingly, CCDC6 knock-in mice develop 
thyroid hyperplasia associated to an enhanced 
CREB1 activity (Leone V et al., 2015), supporting a 
likely role of the haploinsufficiency of CCDC6 
expression in the development of thyroid papillary 
carcinomas carrying the RET/PTC1 rearrangements. 
High-throughput proteomic screening predicted the 
interaction between CCDC6 and the catalytic 
subunit of Protein Phosphatase 4 (PP4c) (Ewing et 
al., 2007) that has been confirmed in vitro and in 
vivo (Merolla et al., 2012). Moreover, it has been 
demonstrate that cells depleted of CCDC6 have an 
enhanced phosphatase activity directed toward the 
phosphorylation of the H2AX protein in response to 
ionizing radiation (IR). Loss of CCDC6 also affects 
the DNA damage induced G2 arrest, promoting the 
overcome of G2/M checkpoint.  
Furthermore, loss of CCDC6 affects the DNA repair 
mechanisms in G2 and increases the levels of the 
error prone mechanism of repair, 'Non Homologous 
End Joining', (NHEJ ) (Merolla et al., 2012). In 
recent studies it has been reported that the E3 
ubiquitin ligase FBXW7 specifically interacts with 
CCDC6 driving its degradation in a proteasomal 
dependent manner (Zhao et al., 2012). Moreover, 
CCDC6 degradation is impaired in response to DNA 
damage.  
The post translational events that regulate the 
phosphorylation status and the abundance of CCDC6 
during the cell cycle have been also investigated 
(Morra et al., 2015a). 
In human cancers, it has been recently reported that 
the loss of CCDC6 in the Testicular Germ Cell 
Tumors (TGCTs) might aid the spermatogonial cells 
to benefit from a pro-survival pathway in order to 
evade the toxic effects of endogenous oxidants and 
then promote testicular neoplastic growth (Staibano 
et al., 2013). Furthermore, in NSCLC, TMA 
immunostaining for CCDC6 revealed low CCDC6 
expression in about 30% of the NSCLC analyzed (45 
out of 138), besides the low penetrance of reported 
CCDC6 mutations or CCDC6/RET rearrangements. 
The defective expression of CCDC6 in NSCLC has 
been negatively correlated to DFS and OS (Morra et 
al., 2015b). Moreover, the defective expression of 
CCDC6 causes an impairment of DNA repair by 
homologous recombination (HR) in NSCLC cells, 
making these cells sensitive to PARP inhibitors. 
Finally, it has been reported that beside the CCDC6 
sporadic mutations, molecular alterations in CCDC6 
modifiers, such as Fbxw7 E3 ubiquitin ligase or 
USP7 de-ubiquitinating enzyme, may also account 
for the impairment of the CCDC6 turnover and may 
be critical in optimizing personalized therapy. About 
20% of primary NSCLC exhibit reduced USP7 
expression and also show barely detectable levels of 
CCDC6 that may increase their sensitivity to PARP 
inhibitors (Morra et al., 2015a). Therefore, the 
indication of CCDC6 as a novel USP7 substrate 
provides the rational for novel personalized therapy 
in NSCLC patients carrying USP7 deficiency.  
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Fig. 3 : CCDC6 rearrangements. The red arrow shows the RET/PTC1 and the black one shows the CCDC6/PDGFRB 
breakpoint. 
 
Therefore, as the loss of CCDC6 causes an 
impairment of DNA repair by homologous 
recombination, in tumors that harbor low levels of 
USP7, the detection of low levels of its substrate 
CCDC6 should provide the indications for the PARP 
inhibitors treatment (Morra et al., 2015b). 
Homology 
Sequencing analysis of CCDC6 cDNA shows that 
CCDC6 has not significant homology to know 
genes.  
Weak but significant homology to the myosin 
superfamily. 
Mutations 
Germinal 
None 
Somatic 
Fusions:  CCDC6/PDGFRB, CCDC6/ROS1; 
VPS13B/CCDC6; CCDC6/RET; CCDC6/ANK3; 
CCDC6/UBE2D1; CCDC6/PTEN; 
FGFR2/CCDC6; KITLG/CCDC6; CCDC6/LIPI 
Point mutations: TCGAcbioPortal& Cosmic -
CCDC6 - dist 
Implicated in 
Papillary thyroid carcinoma 
Cytogenetics 
inv(10)(q11.2q21) or t(10;10)(q11;q21) 
CCDC6/RET 
t(10;10)(q21;q23) CCDC6/PTEN 
t(8;10)(q22;q21) VPS13B/CCDC6 
Hybrid/Mutated gene 
CCDC6/RET 
CCDC6/PTEN 
VPS13B/CCDC6 
 
Abnormal protein 
The fusion protein CCDC6/RET contains the first 
101 aminoacids including part of CCDC6 coiled coil 
domain and the entire tyrosine kinase domain of 
RET.  
The fusion is a constitutively active tyrosine kinase. 
Oncogenesis 
In transgenic mice the fusion CCDC6/RET gave rise 
to mammary adenocarcinomas and, less frequently, 
hyperplasia of sebaceous glands and rare benign skin 
tumors.  
CCDC6 knock in mice develop thyroid hyperplasia 
associated with an enhanced CREB1 activity.  
The simultaneous occurrence of CCDC6/PTEN, 
RET/PTC and BRAF mutations have been reported 
in papillary thyroid carcinomas. 
Negative chronic myeloid leukaemia / 
chronic myelomonocytic leukemia 
Disease 
atypical chronic myeloid leukemia 
Prognosis 
Too few cases reported but likely to be similar to 
CML 
Cytogenetics 
t(5;10)(q33;q21.2) 
Hybrid/Mutated gene 
CCDC6/PDGFRB. In a single case analyzed the 
translocation was found to be complex at the 
molecular level. 
Abnormal protein 
Contains the first 368 amminoacids including part of 
CCDC6 coiled coil domain of CCDC6 and the 
leucine zipper of H4 and the entire tyrosine kinase 
domain and transmembrane domain of PDGFRB. 
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Non-small-cell lung cancer (NSCLC) 
Disease 
Adenocarcinoma (NSCLC) 
Cytogenetics 
inv(10)(q11.2q21) or t(10;10)(q11;q21) 
CCDC6/RET 
t(6;10)(q22;q21) CCDC6/ROS1  
t(10;10)(q21;q21) CCDC6/CTNNA3  
t(10;12)(q21;q21) KITLG/CCDC6 
t(10;21)(q21;q11) CCDC6/LIPI 
Hybrid/Mutated gene 
CCDC6/RET 
CCDC6/ROS1 
CCDC6/CTNNA3 
KITLG/CCDC6 
CCDC6/LIPI 
Abnormal protein 
Contains the first 101 amino acids including part of 
CCDC6 coiled coil domain of  CCDC6 
Breast cancer 
Cytogenetics 
t(10;10)(q21;q26) FGFR2/CCDC6  
t(10;10)(q21;q21) CCDC6/UBE2D1 
Hybrid/Mutated gene 
FGFR2/CCDC6  
CCDC6/UBE2D1 
Ovarian epithelial tumor 
Cytogenetics 
t(10;10)(q21;q21) CCDC6/ANK3 
Hybrid/Mutated gene 
CCDC6/ANK3 
 
Breakpoints 
See figure above. 
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